STOCK TITAN

Immunome: Wellington reports 5.32% ownership stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Immunome Inc. (IMNM) common stock is the subject of beneficial-ownership reports by four Wellington entities, each listing 6,041,333 shares. Item 4 states ownership of 5.32% of the class. Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP each report shared voting power of 5,696,467 shares and shared dispositive power of 6,041,333 shares; Wellington Management Company LLP reports shared voting power of 5,695,111 shares and shared dispositive power of 5,872,919 shares. The shares are owned of record by clients of Wellington investment advisers, which have rights to receive dividends or sale proceeds. No client is known to have those rights over more than 5% of the class.

Beneficial ownership 6,041,333 shares Each of the four Wellington reporting entities lists this amount.
Ownership percentage 5.32% Percentage of the class stated in Item 4.
Shared voting power 5,696,467 shares Reported by Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP.
Shared voting power 5,695,111 shares Reported by Wellington Management Company LLP.
Shared dispositive power 6,041,333 shares Reported by Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP.
Shared dispositive power 5,872,919 shares Reported by Wellington Management Company LLP.
beneficially owned regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"Shared Voting Power 5,696,467.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 6,041,333.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Immunome (IMNM) shares do the Wellington entities report?

Each of the four reporting entities lists 6,041,333 shares as beneficially owned; Item 4 states ownership of 5.32% of the class.

Who holds the Immunome shares attributed to Wellington?

The shares are owned of record by clients of Wellington investment advisers, which have the right to receive dividends or direct sale proceeds. No client is known to have those rights over more than 5% of the class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





45257U108

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:11/16/2026
Wellington Group Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:11/16/2026
Wellington Investment Advisors Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:11/16/2026
Wellington Management Company LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:11/16/2026

Keep reading